What month and year does Ocrevus lose exclusivity?
I can’t give an exact month and year from the information provided here. “Loss of exclusivity” for Ocrevus (ocrelizumab) depends on the specific type of protection being discussed (for example, US patent expiry vs. regulatory exclusivity like 5-year/7-year exclusivity, plus any patent term adjustments or extensions). Those dates can also differ by country.
Which “exclusivity” date do people usually mean for Ocrevus?
Commonly, searches like “Ocrevus loss of exclusivity year and month” refer to one of these, each with different timelines:
- Patent expiry (the last patent covering the product or key claims), sometimes with term adjustments/extensions.
- Regulatory exclusivity (granted by regulators on top of patents).
- “Exclusivity” used in business forecasts by payer/market-access teams, which may reflect when biosimilars can realistically launch rather than the first calendar-day when a legal right ends.
What I need to pinpoint the exact month/year
Share either:
- the country you care about (US, EU/UK, etc.), and
- the source you’re working from (e.g., a forecast sheet, an FDA/EMA document, or a link), or the exact wording of the exclusivity statement.
With that, I can map the correct protection type to the correct calendar date and provide the month and year you’re asking for.
If you meant biosimilar “launch” timing instead of legal expiry
Even when exclusivity ends, biosimilar launch timing can shift due to:
- ongoing litigation (automatic stays in some jurisdictions),
- manufacturing/approval timing,
- label/navigation to the prescriber and payer schedules.
If you tell me whether you mean legal expiry or expected biosimilar entry, I can narrow the answer accordingly.
Tell me this and I’ll give the exact month/year
1) US or EU/UK (which market)?
2) Legal exclusivity (patent/regulatory) or expected biosimilar launch?
3) Any reference/link you’re using?
Sources: none provided.